Glenmark Pharmaceuticals announced its unaudited financial results for the quarter ended June 30, 2026. The company reported substantial revenue and profit figures, alongside a limited review report from its auditors. Key corporate actions include the approval of financial results and the setting of August 31, 2026, as the record date for determining dividend entitlement for the financial year ended March 31, 2026. The 48th AGM is scheduled for September 11, 2026.
Glenmark Pharmaceuticals Announces Q1 FY27 Results
Glenmark Pharmaceuticals Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors, in its meeting held on July 31, 2026, approved these results along with the accompanying Limited Review Report.
Key Financial Highlights (Standalone)
For the quarter ended June 30, 2026, Glenmark Pharmaceuticals reported total income of ₹25,504.04 million. The profit after tax for the period stood at ₹7,356.37 million. Total comprehensive income attributable to owners of the company was ₹7,362.43 million. Earnings per share (EPS) were reported at ₹26.07 basic and diluted.
Consolidated Financial Performance
On a consolidated basis, for the quarter ended June 30, 2026, the total income was ₹40,842.47 million. The profit after tax amounted to ₹4,828.28 million, with total comprehensive income attributable to owners of the company at ₹5,233.66 million. The consolidated diluted EPS was ₹17.11.
Annual General Meeting and Record Date
The Company has scheduled its 48th Annual General Meeting (AGM) for Friday, September 11, 2026, at 2:00 P.M. The AGM will be conducted via video-conferencing or other audio-visual means. The proceedings will be deemed to be held at the Corporate Office of the Company. Furthermore, Monday, August 31, 2026, has been fixed as the record date for the purpose of determining the entitlement of dividend for the financial year ended March 31, 2026.
Policy Amendments and Committee Reconstitution
The Board also approved amendments and reviews for several key policies, including the Policy on Related Party Transactions, Policy on Determination of Materiality for Disclosures, Insider Trading Policy, Dividend Distribution Policy, and Nomination and Remuneration Policy. Additionally, the Board approved the reconstitution of the Risk Management Committee, with Ms. Patricia Andrews appointed as Chairperson, effective August 01, 2026.
Notes on Financials
The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and the Board of Directors and have undergone a limited review by statutory auditors. The Chief Operating Decision Maker reviews performance at the pharmaceutical business level, resulting in a single reportable segment: Pharmaceuticals. The results also note exceptional items related to the transfer of Nebulizer brands and a provision for antitrust lawsuits.
Source: BSE
